Polisano F, Ryals AD, Pannocchia G, Landi A. MPC based optimization applied to treatment of HCV infections.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2021;
210:106383. [PMID:
34496321 DOI:
10.1016/j.cmpb.2021.106383]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Accepted: 08/24/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND AND OBJECTIVE
The recent introduction of antivirals for the treatment of the hepatitis C virus opens new frontiers but also poses a significant burden on public health systems. This paper presents a simulation study in which model predictive control (MPC) is proposed for optimizing the therapy aiming to obtain a reduction of the costs of therapy, while maintaining the best pharmacological control of the infection.
METHODS
A dynamic model describing the evolution of hepatitis C is deployed as internal model for MPC implementation, using nominal values of parameters. Different closed-loop simulations are presented both in nominal and in mismatch conditions. In addition, a more easily implementable treatment is proposed, which is based on a discrete dosage approach, where days on/off therapy are considered instead of continuous therapy modulation.
RESULTS
Results show that therapy modulation allows one to achieve the same infection evolution as with full therapy, with a reduction of drug consumption between 10% and 40%. The alternative discrete dosage approach shows similar results achieved with therapy modulation, both in terms of therapy effectiveness and drug consumption reduction.
CONCLUSIONS
The proposed model predictive control therapy optimization strategies appear to be effective, implementable and robust to model errors. It therefore represents a potentially useful approach to alleviate the burden of HCV therapy cost on national health systems.
Collapse